AUDENTES THERAPEUTICS INC's ticker is BOLD and the CUSIP is 05070R104. A total of 125 filers reported holding AUDENTES THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 2.39 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $155,000 | +1007.1% | 2,600 | +271.4% | 0.00% | – |
Q4 2018 | $14,000 | -80.3% | 700 | -61.1% | 0.00% | – |
Q3 2018 | $71,000 | +4.4% | 1,800 | 0.0% | 0.00% | – |
Q2 2018 | $68,000 | +25.9% | 1,800 | 0.0% | 0.00% | – |
Q1 2018 | $54,000 | -3.6% | 1,800 | 0.0% | 0.00% | – |
Q4 2017 | $56,000 | +12.0% | 1,800 | 0.0% | 0.00% | – |
Q3 2017 | $50,000 | +47.1% | 1,800 | 0.0% | 0.00% | – |
Q2 2017 | $34,000 | +13.3% | 1,800 | 0.0% | 0.00% | – |
Q1 2017 | $30,000 | -6.2% | 1,800 | 0.0% | 0.00% | – |
Q4 2016 | $32,000 | 0.0% | 1,800 | 0.0% | 0.00% | – |
Q3 2016 | $32,000 | – | 1,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NEXTHERA CAPITAL LP | 294,013 | $11,131,000 | 9.27% |
GREAT POINT PARTNERS LLC | 1,922,937 | $72,802,000,000 | 8.08% |
Versant Venture Management, LLC | 553,916 | $20,971,260,000 | 6.11% |
Foresite Capital Management III, LLC | 315,331 | $11,938,000 | 3.92% |
Casdin Capital, LLC | 965,000 | $36,534,900,000 | 3.42% |
Sofinnova Investments, Inc. | 933,640 | $35,348,000 | 3.25% |
Opaleye Management Inc. | 280,000 | $10,601,000 | 3.23% |
Redmile Group, LLC | 2,972,167 | $112,526,000 | 3.18% |
PFM Health Sciences, LP | 3,228,679 | $122,238,000 | 2.32% |
Eversept Partners, LP | 159,526 | $6,039,654 | 1.69% |